Biotechnology patient access lobbying enters new phase with Cellares

Biotechnology patient access has become a focal point in Washington as Cellares Corp. makes its first foray into federal lobbying. The biotech company retained Hogan Lovells US LLP in 2025 to advocate for patient access to biotechnology innovation, marking a strategic entry into the regulatory landscape as Congress actively considers legislation affecting cell and gene therapy access and reimbursement.

By the Numbers

Cellares has spent $40,000 on lobbying since starting in 2025. The company uses only external lobbying through Hogan Lovells US LLP. The lobbying team consists of one registered lobbyist: Cybil Gregory Roehrenbeck. Roehrenbeck previously served as a Legislative Assistant for Rep. Walter Jones Jr. and brings extensive experience representing biotech clients including Legend Biotech Corp. and Cabaletta Bio Inc.

Broader Congressional Context

Congress is actively addressing cell and gene therapy regulation and access. Sen. Tim Scott questioned Dr. Mehmet Oz about developing “cell and gene therapy access models” for Medicare and Medicaid during confirmation hearings. Multiple bills target the regulatory framework for human cell and tissue products. The legislative environment shows bipartisan support for advanced therapy innovation and patient access initiatives.

Cellares’ Lobbying Agenda

Cellares focuses exclusively on health issues related to patient access to biotechnology innovation. The company markets itself as solving manufacturing challenges for cell therapies through its “Cell Shuttle” platform. Their lobbying aligns with congressional efforts to establish reimbursement models and regulatory frameworks for advanced therapies. No specific legislation is mentioned in their registration.

Competitive Landscape

Several organizations lobby on similar cell and gene therapy issues. Vertex Pharmaceuticals Inc. targets the “CMMI’s Cell and Gene Therapy Access model for Sickle Cell Disease.” Danaher Corporation advocates on “genomic medicines and biotechnology, cell and gene therapy.” The American Society of Hematology also pushes for cell and gene therapy models, creating a competitive landscape where Cellares must differentiate its manufacturing-focused approach.

Key Legislation in Motion

Three key bills are moving through Congress that directly impact Cellares’ lobbying priorities:

  • HCT/P Modernization Act of 2025 (H.R. 340) – Aims to streamline regulatory oversight of human cell and tissue products
  • Stem Cell Therapeutic and Research Reauthorization

Spot something wrong? Report an issue with this article